EMA-CO方案治疗21例耐药滋养细胞肿瘤的疗效分析

摘要

Objective To investigate the efficacy of EMA-CO regimen in the treatment of drug-resistant gestational trophoblastic tumor(GTN).Methods The clinical efficacy and side effects of EMA-CO regimen in the treatment of GTN resistant patients with first-line 5-FU single drug chemotherapy regimen were retrospectively reviewed in 21 cases treated in Sichuan Provincial People's Hospital from October 2005 to October 2015.Results The cure rate of EMA-CO regimen for resistant GTN was up to 90.48％.The main adverse reactions were bone marrow suppression,gastrointestinal reactions and mild liver damage.Among them,bone marrow suppression of degree Ⅲ accounted for 9.57％,bone marrow suppression of degree Ⅳ accounted for 3.19％,digestive tract reaction of degree Ⅰ-Ⅱ accounted for 39.36％,liver function damage of degree Ⅰ-Ⅱ accounted for 13.83％,and the rest of patients did not have serious complications.Conclusion The EMA-CO regimen has definite efficacy,mild side effects,and is easy to accept as a preferred chemotherapy regimen for drug-resistant GTN,%目的 了解EMA-CO方案治疗耐药妊娠滋养细胞肿瘤(GTN)的疗效.方法 回顾性总结在我院2005年10月至2015年10月期间收治的21例应用EMA-CO方案治疗对一线5-FU单药化疗方案耐药GTN患者的临床疗效及不良反应.结果 EMA-CO方案对于耐药GTN的治愈率可达90.48％,不良反应主要是骨髓抑制、消化道反应和肝功轻度损害,其中Ⅲ度骨髓抑制占9.57％,Ⅳ度骨髓抑制占3.19％,Ⅰ～Ⅱ度消化道反应占39.36％,Ⅰ～Ⅱ度肝功能损害占13.83％,其余未发生严重并发症.结论 EMA-CO方案的疗效肯定,不良反应轻,患者易于接受,可作为耐药GTN的首选化疗方案.